Compare EVTL & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | PBYI |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United Kingdom | United States |
| Employees | 454 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.7M | 343.9M |
| IPO Year | N/A | 2011 |
| Metric | EVTL | PBYI |
|---|---|---|
| Price | $2.16 | $7.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $12.70 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 234.0K |
| Earning Date | 03-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $3.03 |
| 52 Week High | $7.60 | $7.90 |
| Indicator | EVTL | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 34.19 | 47.58 |
| Support Level | $1.90 | $6.32 |
| Resistance Level | $2.89 | $7.31 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 2.68 | 51.42 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.